RU2006137794A - Химические составы, композиции и способы их использования - Google Patents

Химические составы, композиции и способы их использования Download PDF

Info

Publication number
RU2006137794A
RU2006137794A RU2006137794/04A RU2006137794A RU2006137794A RU 2006137794 A RU2006137794 A RU 2006137794A RU 2006137794/04 A RU2006137794/04 A RU 2006137794/04A RU 2006137794 A RU2006137794 A RU 2006137794A RU 2006137794 A RU2006137794 A RU 2006137794A
Authority
RU
Russia
Prior art keywords
optionally substituted
composition according
chemical composition
group
substituted
Prior art date
Application number
RU2006137794/04A
Other languages
English (en)
Other versions
RU2413720C2 (ru
Inventor
Ксиангпинг КВИАН (US)
Ксиангпинг Квиан
Эндрю Ай МАКДОНАЛЬД (US)
Эндрю Ай МАКДОНАЛЬД
Хан-Джийе ЖУ (US)
Хан-Джийе ЖУ
Льюк В. АШКРАФТ (US)
Льюк В. Ашкрафт
Бинг ЯО (US)
Бинг ЯО
Хонг ДЖИАНГ (US)
Хонг ДЖИАНГ
Дженнифер Куо Чен ХУАНГ (US)
Дженнифер Куо Чен ХУАНГ
Джианчао ВАНГ (US)
Джианчао Ванг
Дэвид Дж. Младший МОРГАНС (US)
Дэвид Дж. Младший МОРГАНС
Брэдли П. МОРГАН (US)
Брэдли П. Морган
Густав БЕРДЖИНС (US)
Густав Берджинс
Дашь нт ДХЭНЭК (US)
Дашьянт ДХЭНЭК
Стивен Д. НАЙТ (US)
Стивен Д. Найт
Николас Д. АДАМС (US)
Николас Д. Адамс
Синти А. ПЭРРИШ (US)
Синтия А. Пэрриш
Кевин ДАФФИ (US)
Кевин ДАФФИ
Дюк ФИТЧ (US)
Дюк ФИТЧ
Розана ТЭДЭСКО (US)
Розана ТЭДЭСКО
Original Assignee
Цитокинетикс, Инк. (Us)
Цитокинетикс, Инк.
Смитклайн Бихем Корпорейшн. (Us)
Смитклайн Бихем Корпорейшн.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цитокинетикс, Инк. (Us), Цитокинетикс, Инк., Смитклайн Бихем Корпорейшн. (Us), Смитклайн Бихем Корпорейшн. filed Critical Цитокинетикс, Инк. (Us)
Publication of RU2006137794A publication Critical patent/RU2006137794A/ru
Application granted granted Critical
Publication of RU2413720C2 publication Critical patent/RU2413720C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/62—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with triarylmethyl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (46)

1. По крайней мере один химический состав, выбранный из соединений по формуле I
Figure 00000001
и фармацевтически приемлемые соли, сольваты, хелаты, нековалентные комплексы, пролекарства и их смеси, отличающийся тем, что
R1 является возможно замещенным арилом, возможно замещенным гетероциклилом или возможно замещенным гетероарилом.
Х является -СО или -SO2-;
R2 является водородом или возможно замещенным низшим алкилом;
W является -CR4-, -СН2 CR4-, или N;
R3 является -СО- R7, водородом, возможно замещенным алкилом, возможно замещенным гетероциклилом, циано, возможно замещенным сульфонилом или возможно замещенным арилом;
R4 является водородом или возможно замещенным алкилом;
R5 является водородом, гидроксильной группой, возможно замещенной аминогруппой, возможно замещенным гетероциклилом или возможно замещенным низшим алкилом;
R6 является водородом, возможно замещенным алкилом, возможно замещенной алкоксигруппой, возможно замещенной арилоксигруппой, возможно замещенной гетероарилоксигруппой, возможно замещенным алкоксикарбонилом, возможно замещенным аминокарбонилом, возможно замещенным арилом, возможно замещенным гетероарилом возможно замещенным гетероциклилом или возможно замещенным аралкилом; и
R7 является возможно замещенным низшим алкилом, возможно замещенным арилом, гидроксильной группой, возможно замещенным амино, возможно замещенным аралкоси, или возможно замещенным алкокси;
при условии что если W является N, тогда R5 не является гидроксильной группой или возможно замещенной аминогруппой, и R6 не является возможно замещенной алкоксигруппой, возможно замещенной аралкоксигруппой, возможно замещенной гетероарилокси группой или возможно замещенной аминогруппой.
2. По крайней мере один химический состав по п.1, отличающийся тем, что R1 является возможно замещенным арилом.
3. По крайней мере один химический состав по п.2, отличающийся тем, что R1 является возможно замещенным фенилом.
4. По крайней мере один химический состав по п.3, отличающийся тем, что R1 является фенилом, замещенным одной, двумя или тремя группами, независимо выбранными из возможно замещенного гетероциклила, возможно замещенного алкила, сульфонила, галогруппы, возможно замещенной аминогруппы, возможно замещенного сульфонила, возможно замещенной алкоксигруппы, возможно замещенной арилоксигруппы, возможно замещенной гетероарилоксигруппы; ацила, гидроксильной группы, нитро, пиано, возможно замещенного арила и возможно замещенного гетероарила.
5. По крайней мере один химический состав по п.4, отличающийся тем, что R1 является 3-гало-4-изопропокси-фенилом или 3-циано-4-изопропокси-фенилом.
6. По крайней мере один химический состав по п.1, отличающийся тем, что Х является -СО-.
7. По крайней мере один химический состав по п.1, отличающийся тем, что соединение формулы I выбрано из соединений формулы II
Figure 00000002
при этом R11 является возможно замещенным гетероциклилом, возможно замещенным низшим алкилом, нитрогруппой, цианогруппой, водородом, сульфонилом или галогруппой;
R12 является водородом, галогруппой, возможно замещенным алкилом, возможно замещенной аминогруппой, возможно замещенным сульфонилом, возможно замещенной алкоксигруппой, возможно замещенной арилоксигруппой, возможно замещенным гетероциклилом или возможно замещенным гетероарилокси; и
R13 является водородом, ацилом, возможно замешенным алкилом, возможно замещенной алкоксигруппой, галогруппой, гидроксильной группой, нитро, циано, возможно замещенной аминогруппой, алкилсульфонилом, алкилсульфонамидо, алкилсульфонилом, карбоксиалкилом, аминокарбонилом, возможно замещенным арилом или возможно замещенным гетероарилом.
8. По крайней мере один химический состав по п.1, отличающийся тем, что W является -CR4-.
9. По крайней мере один химический состав по п.1, отличающийся тем, что R4 является водородом.
10. По крайней мере один химический состав по п.1, отличающийся тем, что R5 является водородом, гидроксильной группой или возможно замещенным низшим алкилом.
11. По крайней мере один химический состав по п.10, отличающийся тем, что R5 является водородом.
12. По крайней мере один химический состав по п.7, отличающийся тем, что соединение формулы II выбрано из соединений формулы III
Figure 00000003
13. По крайней мере один химический состав по п.1, отличающийся тем, что R3 является -СО- R7, водородом; возможно замещенным низшим алкилом; циано; возможно замещенным сульфонилом; возможно замещенным арилом; или возможно замещенным гетероциклилом.
14. По крайней мере один химический состав по п.13, отличающийся тем, что R3 является возможно замещенным низшим алкилом.
15. По крайней мере один химический состав по п.14, отличающийся тем, что R3 является низшим алкилом, возможно замещенным гидроксильной группой или ее эфиром фосфата, низшим алкилом, возможно замещенным низшей алкоксигруппой, низшим алкилом, возможно замещенным аминогруппой или низшим алкилом, возможно замещенным СО- R7, при этом R7 является гидроксильной группой или возможно замещенной аминогруппой.
16. По крайней мере один химический состав по п.15, отличающийся тем, что R3 является низшим алкилом, возможно замещенным гидроксильной группой или ее эфиром фосфата, или низшим алкилом, возможно замещенным аминогруппой.
17. По крайней мере один химический состав по п.12, отличающийся тем, что соединение формулы III выбрано из соединений формулы IV
Figure 00000004
18. По крайней мере один химический состав по п.1, отличающийся тем, что R6 является возможно замещенным арилом, возможно замещенным гетероарилом, возможно замещенным гетероциклилом или возможно замещенным алкилом.
19. По крайней мере один химический состав по п.18, отличающийся тем, что R6 является фенилом, замещенным одним или двумя из следующих заместителей: возможно замещенный гетроарил, возможно замещенная аминогруппа, арилоксигруппа, галогруппа, гидроксиметил, гидрокси, циано, алкокси, фенил, феноксигруппа, метилендиоксигруппа, этилендиоксигруппа, сульфонил, аминокарбонил, карбоксигруппа, алкоксикарбонил, нитрогруппа, гетероарилоксигруппа, арилкоксигруппа и возможно замещенный гетероциклил.
20. По крайней мере один химический состав по п.12, отличающийся тем, что соединение формулы III выбрано из соединений формулы V
Figure 00000005
при этом R14 является возможно замещенным гетероарилом; и
R15 выбран из водорода, галогруппы, гидроксильной группы и низшего алкила.
21. По крайней мере один химический состав по п.20, отличающийся тем, что R14 выбран из 7,8-дигидро-имидазо[1,2-с][1,3]оксазин-2-ила, 3а,7а-дигидро-1Н-бензоимидазол-2-ила, имидазо[2,1-b]оксазол-6-ила, оксазол-4-ила, 5,6,7,8-тетрагидро-имидазо[1,2-а]пиридин-2-ила, 1Н-[1,2,4]тризол-3-ила, 2,3-дигидро-имидазол-4-ила, 1Н-имидазол-2-ила, имидазо[1,2-а]пиридин-2-ила, тиазол-2-ила, тиазол-4-ила, пиразол-3-ила и 1Н-имидазол-4-ила, каждый из которых возможно замещен одной, двумя или тремя группами, выбранными из возможно замещенного низшего алкила, галогруппы, ацила, сульфонила, цианогруппы, нитро группы, возможно замещенной аминогруппы и возможно замещенного гетероарила.
22. По крайней мере один химический состав по п.21, отличающийся тем, что R14 выбран из 1Н-имидазол-2-ила, имидазо[1,2-а]пиридин-2-ила и 1Н-имидазол-4-ила, каждый из которых возможно замещен одной, двумя или тремя группами, выбранными из возможно замещенного низшего алкила, галогруппы, и ацила.
23. По крайней мере один химический состав по п.20, отличающийся тем, что R15 является водородом.
24. По крайней мере один химический состав по п.12, отличающийся тем, что соединение формулы II выбрано из соединений формулы VI
Figure 00000006
25. По крайней мере один химический состав по п.12, отличающийся тем, что соединение по формуле II выбрано из соединений формулы VII
Figure 00000007
при этом R9 выбран из возможно замещенной алкоксигруппы, возможно замещенной циклоалкоксигруппы, возможно замещенной арилалкоксигруппы, возможно замещенной аминогруппы и возможно замещенного низшего алкила.
26. По крайней мере один химический состав по п.25, отличающийся тем, что R9 является низшим алкилом, замещенным гидроксильной группой или возможно замещенной аминогруппой.
27. По крайней мере один химический состав по п.26, отличающийся тем, что R9 является низшим алкилом, замещенным гидроксильной группой, аминогруппой, N-метиламино или N,N-диметиламиногруппой.
28. По крайней мере один химический состав по п.7, отличающийся тем, что R11 является водородом, циано, нитро или галогруппой.
29. По крайней мере один химический состав по п.28, отличающийся тем, что R11 является хлоро или цианогруппой.
30. По крайней мере один химический состав по п.7, отличающийся тем, что R12 является возможно замещенной низшей алкоксигруппой, возможно замещенным низшим алкилом или возможно замещенной аминогруппой.
31. По крайней мере один химический состав по п.30, отличающийся тем, что R12 является низшим алкокси или 2,2,2-трифторо-1-метил-этоксигруппой.
32. По крайней мере один химический состав по п.31, отличающийся тем, что R12 является проксигруппой или 2,2,2-трифторо-1-метил-этоксигруппой.
33. По крайней мере один химический состав по п.7, отличающийся тем, что R13 является водородом.
34. По крайней мере один химический состав по п.1, отличающийся тем, что R2 является водородом.
35. По крайней мере один химический состав по п.1, выбранный из соединений, описанных в Таблице 1, 2, 3, 4, 5, или 6 и фармацевтически приемлемые соли, сольваты, хелаты, нековалентные комплексы, пролекарства и их смеси.
36. По крайней мере один химический состав по п.35, который является эфиром фосфата соединений, выбранных из описанных в Таблице 1, 2, 3, 4, 5 или 6.
37. Композиция, включающая фармацевтический наполнитель и по крайней мере один химический состав по п.1.
38. Композиция по п.37, отличающаяся тем, что вышеупомянутая композиция далее включает химиотерапевтический агент, отличный от соединения по формуле I.
39. Композиция по п.38, отличающаяся тем, что вышеупомянутая композиция далее включает таксан, винка алкалоид или ингибитор топоизомеразы I.
40. Способ модулирования активности CENP-E кинезина, включающий вступление в контакт вышеупомянутого кинезина с эффективным количеством по крайней мере одного химического состава по п.1.
41. Способ ингибирования CENP-E, включающий вступление в контакт вышеупомянутого кинезина с эффективным количеством по крайней мере одного химического состава по п.1.
42. Способ лечения клеточно-пролиферативного заболевания, включающий назначения нуждающемуся в нем субъекту по крайней мере одного химического состава по п.1.
43. Способ лечения клеточно-пролиферативного заболевания, включающий назначения нуждающемуся в ней субъекту по крайней мере одной композиции по п.37.
44. Способ по п.42, отличающийся тем, что вышеупомянутое заболевание выбрано из группы, состоящей из рака, гиперплазии, рестеноза, кардиогипертрофии, иммунных нарушений и воспаления.
45. Использование при изготовлении медицинского препарата для лечения клеточно-пролиферативного заболевания по крайней мере одного химического состава по любому из пп.1-36.
46. Использование по крайней мере одного химического состава, определенного в п.45, для изготовления медицинского препарата для лечения нарушений, связанных с активностью кинезина CENP-E.
RU2006137794/04A 2004-05-06 2005-05-06 Химические составы, композиции и способы их использования RU2413720C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56951004P 2004-05-06 2004-05-06
US60/569,510 2004-05-06
US11/121,709 US7618981B2 (en) 2004-05-06 2005-05-03 Imidazopyridinyl-benzamide anti-cancer agents
US11/121,709 2005-05-03

Publications (2)

Publication Number Publication Date
RU2006137794A true RU2006137794A (ru) 2008-05-10
RU2413720C2 RU2413720C2 (ru) 2011-03-10

Family

ID=35320725

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006137794/04A RU2413720C2 (ru) 2004-05-06 2005-05-06 Химические составы, композиции и способы их использования

Country Status (20)

Country Link
US (1) US7618981B2 (ru)
EP (1) EP1742907A4 (ru)
JP (1) JP4805916B2 (ru)
KR (1) KR101026861B1 (ru)
CN (1) CN102557982A (ru)
AR (1) AR053748A1 (ru)
AU (1) AU2005240178B2 (ru)
BR (1) BRPI0510663A (ru)
CA (1) CA2565695C (ru)
IL (1) IL178860A (ru)
MA (1) MA28646B1 (ru)
MX (1) MXPA06012796A (ru)
MY (1) MY146548A (ru)
NO (1) NO20065504L (ru)
NZ (1) NZ550811A (ru)
PE (1) PE20060361A1 (ru)
PL (1) PL212494B1 (ru)
RU (1) RU2413720C2 (ru)
TW (1) TWI363628B (ru)
WO (1) WO2005107762A2 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795448B2 (en) * 2004-05-06 2010-09-14 Cytokinetics, Incorporated Imidazoyl-benzamide anti-cancer agents
US7504413B2 (en) * 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
WO2006002236A1 (en) 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer
TWI371272B (en) * 2005-07-19 2012-09-01 Sankyo Co Substituted propanamide derivatives and pharmaceutical compositions thereof
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
US20070135435A1 (en) * 2005-11-02 2007-06-14 Xiangping Qian Certain chemical entities, compositions, and methods
US20070197640A1 (en) * 2005-11-02 2007-08-23 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
KR20090064458A (ko) 2006-10-20 2009-06-18 머크 앤드 캄파니 인코포레이티드 봄베신 수용체 아형-3 조절제로서의 치환된 이미다졸
US8183275B2 (en) 2006-10-20 2012-05-22 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
US8106070B2 (en) 2006-10-20 2012-01-31 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
KR20090097210A (ko) 2007-01-05 2009-09-15 노파르티스 아게 키네신 방추체 단백질 (ｅｇ－５) 억제제로서의 이미다졸 유도체
NZ577910A (en) 2007-01-12 2012-04-27 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
TR201818979T4 (tr) * 2008-09-09 2019-01-21 Hoffmann La Roche Açil sülfonamidlerin polimorfları.
JP2013510092A (ja) * 2009-11-05 2013-03-21 レクシコン ファーマシューティカルズ インコーポレイテッド がんの治療のためのトリプトファンヒドロキシラーゼ阻害剤
EP2582682B1 (en) 2010-06-17 2015-01-14 Cytokinetics, Inc. Mitotic kinesin inhibitors for use in the treatmetnof pulmonary arterial hypertension
WO2012008507A1 (ja) * 2010-07-14 2012-01-19 武田薬品工業株式会社 癌の治療剤
JP5705984B2 (ja) 2010-08-23 2015-04-22 ノバルティス アーゲー Ｎｅｐ阻害剤を製造するための中間体の調製方法
WO2013026773A1 (en) 2011-08-19 2013-02-28 Dsm Ip Assets B.V. Synthesis of r-biphenylalaninol
MX2014004503A (es) 2011-10-17 2015-01-16 Biotheryx Inc Biaril alquil amidas sustituidas.
TWI654180B (zh) * 2012-06-29 2019-03-21 美商艾佛艾姆希公司 殺真菌之雜環羧醯胺
RU2617392C2 (ru) * 2012-08-13 2017-04-24 Эррэй Биофарма Инк. Применение arry-520 для лечения рака у пациентов с низким уровнем акг
KR20150095779A (ko) * 2012-12-13 2015-08-21 글락소스미스클라인 엘엘씨 제스트 인핸서 상동체 2 억제제
ES2864349T3 (es) * 2013-06-11 2021-10-13 Receptos Llc Nuevos moduladores del receptor GLP-1
JP2016523955A (ja) 2013-07-10 2016-08-12 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ Ｚｅｓｔｅホモログ２エンハンサー阻害剤
WO2015037460A1 (ja) * 2013-09-10 2015-03-19 住友化学株式会社 光学活性な３－（ビフェニル－４－イル）－２－［（ｔ－ブトキシカルボニル）アミノ］プロパン－１－オールの製造方法
NO2699580T3 (ru) 2014-01-24 2018-02-24
IS2977B (is) * 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
CN107635959A (zh) * 2015-06-10 2018-01-26 住友化学株式会社 氨基甲酸酯化合物的制造方法
JP2021530525A (ja) 2018-07-17 2021-11-11 インスメッド インコーポレイテッド ループス腎炎を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
CN111253369A (zh) * 2018-11-30 2020-06-09 上海医药集团股份有限公司 一种苯磺酸盐、其制备方法及其在制备达比加群酯中的应用
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8005M (ru) 1967-05-24 1970-07-27
GB1442707A (en) * 1973-07-07 1976-07-14 Yoshitomi Pharmaceutical Substituted phenylalkanoic acids and their derivatives and pharma ceutical compositions thereof
JPS5910675B2 (ja) * 1976-03-22 1984-03-10 ウェルファイド株式会社 アラルキルアミン誘導体
DE2905883A1 (de) 1979-02-16 1980-08-28 Boehringer Sohn Ingelheim Radioimmuntest fuer clonidin
EP0278530A3 (de) * 1980-08-30 1989-08-02 Hoechst Aktiengesellschaft Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung
FR2496653A1 (fr) * 1980-12-22 1982-06-25 Delalande Sa Nouveaux derives aminoalcoyl heterocycliques, leurs procedes de preparation et leur application en therapeutique
SE8107537L (sv) * 1980-12-22 1982-06-23 Delalande Sa Nya derivat av heterocykliska aminoalcoyler, deras framstellningssett och deras terapeutiska anvendning
US4579866A (en) * 1984-05-29 1986-04-01 Usv Pharmaceutical Corp. Phenylacetamides as anti-allergy, anti-asthma and anti-inflammatory agents
CN1145075A (zh) * 1994-03-28 1997-03-12 贾帕特有限公司 内皮素受体拮抗剂
JP3504738B2 (ja) * 1994-09-09 2004-03-08 オリンパス株式会社 電子的撮像装置及び電子的撮像システム
JPH11505522A (ja) * 1995-04-21 1999-05-21 ノバルティス・アクチエンゲゼルシャフト エンドセリン阻害剤としてのｎ−アロイルアミノ酸アミド
AU6709596A (en) 1995-08-22 1997-03-19 Japan Tobacco Inc. Amide compounds and use of the same
JPH09124571A (ja) * 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
KR19990001101A (ko) 1997-06-12 1999-01-15 손경식 캐테콜 아미노산 유도체, 이의 제조방법 및 그를 함유한 약제 조성물
DK1005445T3 (da) 1997-08-22 2004-10-04 Hoffmann La Roche N-alkanoylphenylaninderivater
JP2001526881A (ja) 1997-09-11 2001-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 染色体会合に必要とされるプラス端指向性微小管モーター
CN1308604A (zh) 1998-05-12 2001-08-15 美国家用产品公司 用于治疗胰岛素抗性和高血糖的2,3,5－取代的联苯化合物
DE19832009A1 (de) * 1998-07-16 2000-01-20 Hoechst Marion Roussel De Gmbh 2,5-Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharamazeutische Präparate
US6204282B1 (en) * 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US6331424B1 (en) 1999-04-20 2001-12-18 Cytokinetics, Inc. Motor proteins and methods for their use
US6448025B1 (en) 1999-04-20 2002-09-10 Cytokinentics, Inc. Motor proteins and methods for their use
US6387644B1 (en) 1999-04-20 2002-05-14 Cytokinetics, Inc. Motor proteins and methods for their use
WO2000063353A1 (en) 1999-04-20 2000-10-26 Cytokinetics Human kinesins and methods of producing and purifying human kinesins
US6355466B1 (en) 2000-05-17 2002-03-12 Cytokinetics, Inc. Motor proteins and methods for their use
JP3795305B2 (ja) * 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
US20020183249A1 (en) * 1999-08-31 2002-12-05 Taylor Neil R. Method of identifying inhibitors of CDC25
TW200514783A (en) * 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ATE357433T1 (de) * 1999-12-06 2007-04-15 Hoffmann La Roche 4-pyrimidinyl-n-acyl-l-phenylanine
NZ518888A (en) * 1999-12-06 2004-02-27 F 4-pyridinyl-N-acyl-L-phenylalanines
WO2001044154A1 (fr) 1999-12-17 2001-06-21 Mitsubishi Chemical Corporation Derives de dihalopropenyloxybenzene et pesticides contenant ces derniers en tant qu'ingredients actifs
CA2403017A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
AU2001242743A1 (en) * 2000-03-23 2001-10-03 Ajinomoto Co. Inc. Novel phenylalanine derivative
EP1268478B1 (en) * 2000-03-31 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
US6440684B1 (en) 2000-06-12 2002-08-27 Cytokinetics, Inc. Methods of identifying modulators of kinesin motor proteins
WO2001096593A2 (en) 2000-06-15 2001-12-20 Cytokinetics, Inc. Novel motor proteins and methods for their use
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6534309B1 (en) 2000-08-03 2003-03-18 Cytokinetics, Inc. Motor proteins and methods for their use
AU7874001A (en) * 2000-08-18 2002-03-04 Ajinomoto Kk Novel phenylalanine derivatives
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
US6461855B1 (en) 2000-09-29 2002-10-08 Cytokinetics, Inc. Motor proteins and methods for their use
DE60124573T2 (de) * 2000-09-29 2007-06-21 Ajinomoto Co., Inc. Neue phenylalanin-derivate
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
JP4529119B2 (ja) * 2001-08-09 2010-08-25 小野薬品工業株式会社 カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
US7232819B2 (en) * 2001-10-26 2007-06-19 Istituto Di Ricerche Di Biologia P. Angeletti S.P.A. Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
CN1615148A (zh) * 2001-11-21 2005-05-11 伯纳姆研究院 用于对iap抑制卡斯蛋白酶进行去阻遏的方法及组合物
EP1454898A4 (en) * 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
AU2002366362A1 (en) * 2001-12-18 2003-06-30 Bayer Aktiengesellschaft 2-substituted pyrrolo(2.1-a)isoquinolines against cancer
AU2003211560A1 (en) * 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
JPWO2003089410A1 (ja) * 2002-04-19 2005-08-25 協和醗酵工業株式会社 フェニルアラニン誘導体
EP1551962A4 (en) 2002-07-08 2007-08-01 Merck & Co Inc MITOTIC KINESIN BINDING CENTER
CN1703395A (zh) * 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
CN100436429C (zh) * 2003-02-20 2008-11-26 味之素株式会社 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体
CA2517281A1 (en) 2003-03-10 2004-10-14 Pfizer Inc. Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1)
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US20070032536A1 (en) * 2003-05-15 2007-02-08 Xianping Qian Compounds, compositions and methods
JP2007501844A (ja) * 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
WO2005077915A1 (en) * 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. Pyridazinones as antagonists of a4 integrins
US7504413B2 (en) * 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
WO2011031308A1 (en) * 2009-09-09 2011-03-17 Cytokinetics, Incorporated Novel combinations

Also Published As

Publication number Publication date
TWI363628B (en) 2012-05-11
PE20060361A1 (es) 2006-05-05
KR101026861B1 (ko) 2011-04-06
EP1742907A4 (en) 2008-01-02
BRPI0510663A (pt) 2007-12-04
CA2565695C (en) 2013-01-22
MA28646B1 (fr) 2007-06-01
CN102557982A (zh) 2012-07-11
JP2007537163A (ja) 2007-12-20
PL212494B1 (pl) 2012-10-31
PL381704A1 (pl) 2007-06-25
AU2005240178A1 (en) 2005-11-17
US20060094708A1 (en) 2006-05-04
RU2413720C2 (ru) 2011-03-10
KR20070057708A (ko) 2007-06-07
TW200607513A (en) 2006-03-01
AR053748A1 (es) 2007-05-23
IL178860A (en) 2013-04-30
US7618981B2 (en) 2009-11-17
WO2005107762A3 (en) 2006-08-17
JP4805916B2 (ja) 2011-11-02
NZ550811A (en) 2010-07-30
NO20065504L (no) 2007-01-30
AU2005240178B2 (en) 2011-03-17
IL178860A0 (en) 2007-03-08
MY146548A (en) 2012-08-15
MXPA06012796A (es) 2007-05-09
CA2565695A1 (en) 2005-11-17
EP1742907A2 (en) 2007-01-17
WO2005107762A2 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
RU2006137794A (ru) Химические составы, композиции и способы их использования
AU2018226470B2 (en) Compounds for treatment of cancer
ES2708350T3 (es) Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas para el tratamiento de linfomas
CA2736361C (en) Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
WO2006018182A8 (en) Combinations for the treatment of diseases involving cell proliferation
JP2014037426A5 (ru)
JP2008528468A5 (ru)
KR20170109589A (ko) 암 치료를 위한 irs/stat3 이중 조절제 및 항암제의 조합물
JP2017515802A5 (ru)
HUE031367T2 (en) A pharmaceutical combination comprising an Hsp 90 inhibitor and a mTOR inhibitor
CA2473026A1 (en) 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
TW200621762A (en) Novel compounds
EP1986632B1 (en) Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
JP2011527692A5 (ru)
JP2008525417A5 (ru)
RU2009113693A (ru) ЗАМЕЩЕННЫЕ АМИДЫ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ ГИДРОЛИЗА АТФ, СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ В-КЛЕТОК, СПОСОБ ОПРЕДЕЛЕНИЯ Btk В ОБРАЗЦЕ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ВОСПРИИМЧИВЫХ К ИНГИБИРОВАНИЮ АКТИВНОСТИ Btk И СПОСОБ ПОВЫШЕНИЯ ЧУВСТВИТЕЛЬНОСТИ РАКОВЫХ КЛЕТОК К ХИМИОТЕРАПИИ
MX2008014824A (es) Pirazolo[1,5-a]pirimidinas como inhibidores de quinasas dependientes de ciclina.
JP2012505879A5 (ru)
JP2023504230A (ja) Ｐｒｍｔ５阻害剤の組合せ医薬
RU2009103300A (ru) Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии
JP2017501983A5 (ru)
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
CA3115068A1 (en) Method for preparing and delivering bisantrene formulations
CA3145391A1 (en) Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
AU2010247397B2 (en) Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound